Gary Middleton

1 - 10 out of 66Page size: 10

Publications

  1. 2020
  2. E-pub ahead of print

    Use of an integrated pan-cancer oncology enrichment next-generation sequencing assay to measure tumour mutational burden and detect clinically actionable variants

    Valerie Somani, Gary Middleton & Andrew Beggs, 18 Apr 2020, In : Molecular Diagnosis and Therapy.

    Research output: Contribution to journal › Article

  3. E-pub ahead of print

    Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial

    Gary Middleton, Kristian Brock & Lucinda Billingham, 19 Mar 2020, In : The Lancet Respiratory Medicine.

    Research output: Contribution to journal › Article

  4. Published

    A phase I trial of WEE1 inhibition with chemotherapy and radiotherapy as adjuvant treatment, and a window of opportunity trial with cisplatin in patients with head and neck cancer: the WISTERIA trial protocol

    Anthony Kong, Amanda Kirkham, Jo Parish, Rachel Spruce, Gary Middleton, Christina Yap & Hisham Mehanna, 16 Mar 2020, In : BMJ open. 10, 3, e033009.

    Research output: Contribution to journal › Article

  5. E-pub ahead of print

    BRAF-mutant transcriptional subtypes predict outcome of combined BRAF, MEK, and EGFR blockade with dabrafenib, trametinib, and panitumumab in patients with colorectal cancer

    Gary Middleton & 2 others, , 11 Feb 2020, In : Clinical Cancer Research.

    Research output: Contribution to journal › Article

  6. E-pub ahead of print

    The role of B lymphocytes in the immuno-biology of non-small-cell lung cancer

    Akshay Patel, Alex Richter, Mark Drayson & Gary Middleton, 4 Jan 2020, In : Cancer Immunology Immunotherapy.

    Research output: Contribution to journal › Article

  7. 2019
  8. Published

    A Phase II Clinical Trial with Efficacy and Toxicity Outcomes and Baseline Covariates

    Kristian Brock, Lucinda Billingham, Christina Yap & Gary Middleton, 27 Nov 2019, Bayesian Statistics: New Challenges and New Generations. Springer, p. 125-133 (Springer Proceedings in Mathematics & Statistics; vol. 296).

    Research output: Chapter in Book/Report/Conference proceeding › Conference contribution

  9. Published

    MDSC targeting with Gemtuzumab ozogamicin restores T cell immunity and immunotherapy against cancers

    Paul Collins, Suzanne Graef, Sarah Booth, Boris Noyvert, Claire Shannon-Lowe, Gary Middleton, Francis Mussai & Carmela De Santo, 1 Sep 2019, In : EBioMedicine. 47, p. 235-246 12 p.

    Research output: Contribution to journal › Article

  10. Published

    Development and validation of a combined hypoxia and immune prognostic classifier for head and neck cancer

    Jill Brooks, Albert Menezes Antao Nobre De Menezes, Lucinda Archer, Neeraj Lal, Rachel Spruce, Nikos Batis, Jennifer Bryant, Gordon Ryan, Steve Lee, Gary Middleton, Daniel Tennant & 7 others, Andrew Beggs, Jon Deeks, Jean-Baptiste Cazier, Benjamin Willcox & Hisham Mehanna, Sep 2019, In : Clinical Cancer Research. 25, 17, p. 5315-5328 15 p.

    Research output: Contribution to journal › Article

  11. Published

    Mechanisms of immunogenicity in colorectal cancer

    Toritseju Sillo, Andrew Beggs & Gary Middleton, Sep 2019, In : British Journal of Surgery. 106, 10, p. 1283-1297 15 p.

    Research output: Contribution to journal › Review article

  12. 2018
  13. E-pub ahead of print

    Development and validation of a combined metabolic and immune prognostic classifier for head and neck cancer

    Jill Brooks, Lucinda Archer, Rachel Spruce, Nikos Batis, Jennifer Bryant, Andrew Beggs, Daniel Tennant, Gary Middleton, Jean-Baptiste Cazier, Benjamin Willcox, 1 Jun 2018, In : Journal of Clinical Oncology. 36, 15 Suppl, p. 6049-6049

    Research output: Contribution to journal › Abstract

Previous 1 2 3 4 5 6 7 Next